PNC-27
PNC-27 (10mg)
$220USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.275
Reference number
10mg
Lyophilized vial
Peptide containing the HDM2-binding domain of p53 linked to a membrane-penetrating domain. Studied for selective cancer cell targeting in vitro.
Origin
PNC-27 was designed by Bhatt and colleagues at Albert Einstein College of Medicine, combining the p53 MDM2-binding domain (residues 12-26) with a transmembrane-penetrating sequence. The rationale was that cancer cells overexpressing HDM2 on their surface membrane would be selectively targeted by this chimeric peptide.
Research Lineage
Sarafraz-Yazdi et al. and Kanovsky et al. published in vitro studies demonstrating selective cytotoxicity against multiple cancer cell lines while sparing non-transformed cells. The selectivity was attributed to HDM2 surface expression, which is elevated in cancer cells but absent from normal cell membranes. The compound remains in preclinical investigation.
Mechanism of Action
PNC-27 binds to HDM2 (human double minute 2) protein expressed on the surface of cancer cells. This binding is proposed to form transmembrane pores through the cell membrane, leading to necrotic cell death. The selectivity arises because non-cancerous cells do not express HDM2 on their surface membrane, only intracellularly.
Structural Notes
Chimeric peptide. Contains p53 residues 12-26 (HDM2-binding domain) linked to a membrane-penetrating leader sequence. Total length: ~32 amino acids.
Key References
Sarafraz-Yazdi E et al. Int J Mol Med. 2010;26(5):707-14.
Kanovsky M et al. Proc Natl Acad Sci USA. 2001;98(22):12438-43.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.